Mendus AB (publ)
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The com… Read more
Mendus AB (publ) (IMMU) - Total Liabilities
Latest total liabilities as of December 2025: Skr43.26 Million SEK
Based on the latest financial reports, Mendus AB (publ) (IMMU) has total liabilities worth Skr43.26 Million SEK as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Mendus AB (publ) - Total Liabilities Trend (2009–2025)
This chart illustrates how Mendus AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Mendus AB (publ) Competitors by Total Liabilities
The table below lists competitors of Mendus AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aurea SA
PA:AURE
|
France | €127.72 Million |
|
Pharmala Biotech Holdings Inc
OTCQB:MDXXF
|
USA | $1.03 Million |
|
Sparc Technologies Ltd
AU:SPN
|
Australia | AU$1.13 Million |
|
Advancecon Holdings Bhd
KLSE:5281
|
Malaysia | RM385.43 Million |
|
YD More Investments Ltd
TA:MRIN
|
Israel | ILA449.05 Million |
|
VIP Clothing Limited
NSE:VIPCLOTHNG
|
India | ₹1.35 Billion |
|
Lammhults Design Group AB (publ)
ST:LAMM-B
|
Sweden | Skr359.30 Million |
|
Engenco Ltd
AU:EGN
|
Australia | AU$94.56 Million |
Liability Composition Analysis (2009–2025)
This chart breaks down Mendus AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 2.38 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mendus AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mendus AB (publ) (2009–2025)
The table below shows the annual total liabilities of Mendus AB (publ) from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr43.26 Million | -15.54% |
| 2024-12-31 | Skr51.22 Million | -0.02% |
| 2023-12-31 | Skr51.23 Million | -51.65% |
| 2022-12-31 | Skr105.95 Million | +64.92% |
| 2021-12-31 | Skr64.24 Million | -4.92% |
| 2020-12-31 | Skr67.57 Million | +117.62% |
| 2019-12-31 | Skr31.05 Million | -29.96% |
| 2018-12-31 | Skr44.33 Million | -21.66% |
| 2017-12-31 | Skr56.59 Million | +194.98% |
| 2016-12-31 | Skr19.18 Million | +27.39% |
| 2015-12-31 | Skr15.06 Million | +135.04% |
| 2014-12-31 | Skr6.41 Million | -31.06% |
| 2013-12-31 | Skr9.29 Million | +344.35% |
| 2012-12-31 | Skr2.09 Million | +26.97% |
| 2011-12-31 | Skr1.65 Million | -29.20% |
| 2010-12-31 | Skr2.33 Million | +113.00% |
| 2009-12-31 | Skr1.09 Million | -- |